Navegando por Palavras-chave "Estriol"
Agora exibindo 1 - 6 de 6
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosAnálise do estriol salivar em gestantes diabéticas como índice de valor no acompanhamento do bem-estar fetal(Universidade Federal de São Paulo (UNIFESP), 1991) Barros, Sandra Regina Roxo Pessoa de [UNIFESP]; Bertini, Anna Maria Alves [UNIFESP]
- ItemAcesso aberto (Open Access)Avaliação da atividade proliferativa do fibroadenoma mamário apos a administração de anticoncepcional hormonal combinado oral, associado ou não ao estriol(Universidade Federal de São Paulo (UNIFESP), 2007) Estevão, Rodrigo Augusto Fernandes [UNIFESP]; Nazário, Afonso Celso Pinto [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Objetivo: Avaliar a atividade proliferativa do fibroadenoma mamário, por meio da expressão do Ki-67 e do c-myc, após a administração de anticoncepcional hormonal combinado oral, associado ou não ao estriol. Material e métodos: Foram estudadas 32 pacientes com fibroadenoma, das quais 10 constituíram o Grupo 1 e utilizaram anticoncepcional hormonal oral (ACO) composto de levonorgestrel (0,15 mg) e etinilestradiol (0,03 mg), associados a um comprimido de placebo na mesma cápsula, por quatro ciclos consecutivos, com intervalo de sete dias entre os mesmos. As 23 restantes foram alocadas no Grupo 2 e receberam, além do anticoncepcional oral, um comprimido de estriol, na dose de 2 mg, que foi manufaturado conjuntamente com o anticoncepcional, em uma mesma cápsula, sendo utilizado de igual modo que as pacientes do Grupo 1. Realizamos medidas ultrasonográficas dos tumores antes e após a ingestão da medicação e, ao final dos quatro ciclos, praticou-se a exérese cirúrgica dos nódulos, com posterior envio para análise imuno-histoquímica para Ki-67 e c-myc. Resultados: Obtivemos diminuição significante da dimensão (largura) dos fibroadenomas de pacientes usuárias apenas de anticoncepcional oral. No Grupo 1 (ACO com placebo), a largura média dos fibroadenomas antes do tratamento foi de 15,73 mm e, após a utilização de quatro ciclos de ACO, foi de 13,17 mm. Esta redução foi estatisticamente significante (p = 0,043). No Grupo 2 (ACO com estriol), a largura antes e após o tratamento foi de 15,30 e 13,76 mm, respectivamente, diferença não estatisticamente significante (p = 0,157). Não houve alteração das outras dimensões em nenhum dos outros grupos. A análise de Ki-67 e c-myc também não revelou diferenças significantes entre os grupos estudados: 9,16 e 10,54 no Grupo 1 e 10,86 e 17,03 no Grupo 2, respectivamente. Houve, porém, tendência à maior expressão dos marcadores entre as pacientes do Grupo 2. Conclusões: Nossos resultados demonstram não haver diferença significante na expressão de Ki-67 e de c-myc entre as pacientes que receberam ACO isolado ou associado ao estriol. Houve apenas tendência a sua maior expressão entre as usuárias de ACO e estriol. Notamos diminuição significante na largura dos fibroadenomas em usuárias apenas de anticoncepcional oral.
- ItemSomente MetadadadosContribuicao para o estudo do esteriol urinario na segunda metade da gravidez normal(Universidade Federal de São Paulo (UNIFESP), 1970) Ferrari Netto, Eduardo [UNIFESP]
- ItemAcesso aberto (Open Access)Effect of oral contraceptive with and without associated estriol on ultrasound measurements of breast fibroadenoma: randomized clinical trial(Associação Paulista de Medicina - APM, 2007-09-01) Estevão, Rodrigo Augusto Fernandes [UNIFESP]; Nazário, Afonso Celso Pinto [UNIFESP]; Baracat, Edmund Chada [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)CONTEXT AND OBJECTIVE: Fibroadenomas are the most common benign tumors of the female breast. The aim of this study was to evaluate the proliferative activity of breast fibroadenoma as shown by ultrasound measurements, following administration of oral contraceptives with and without associated estriol. DESIGN AND SETTING: This was a randomized, double-blind, placebo-controlled clinical trial carried out in the Mastology Sector, Department of Gynecology, Universidade Federal de São Paulo (UNIFESP). METHODS: We studied 33 women with fibroadenomas. Ten were placed in group 1 and took an oral contraceptive consisting of levonorgestrel and ethinyl estradiol together with placebo material in the same capsule, for four consecutive cycles with a seven-day interval between them. The other 23 patients constituted group 2 and took the oral contraceptive as above together with estriol in the same capsule, in the same way as done by the group 1 patients. We took ultrasound measurements of their tumors (in three dimensions) before and after the intake of medication. At the end of the study, all the patients had their tumors removed by surgery. RESULTS: We observed decreased fibroadenoma width among the users of oral contraceptives with placebo, and this decrease was statistically significant. In the other group, we did not observe any changes (in width, length or height). CONCLUSION: The results confirm that estriol may block the protective effect of oral contraceptives on fibroadenomas, since we observed decreased fibroadenoma width among the group 1 patients but not the group 2 patients.
- ItemAcesso aberto (Open Access)Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial(Associação Paulista de Medicina - APM, 2007-11-01) Estevão, Rodrigo Augusto Fernandes [UNIFESP]; Baracat, Edmund Chada [UNIFESP]; Waitzberg, Angela Flávia Logullo [UNIFESP]; Oshima, Celina Tizuko Fujiyama [UNIFESP]; Nazário, Afonso Celso Pinto [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)CONTEXT AND OBJECTIVE: Mammary fibroadenoma is a disease that affects a large number of women of reproductive age. The aim of this study was to evaluate the proliferative activity of mammary fibroadenoma through expression of Ki-67 and c-myc antigens, following administration of oral contraceptive with or without estriol. DESIGN AND SETTING: Placebo-controlled double-blind randomized clinical trial in the Mastology Sector of the Department of Gynecology, Universidade Federal de São Paulo (UNIFESP). METHODS: Thirty-three fibroadenoma patients were studied. Ten women (group 1) took an oral contraceptive constituted by levonorgestrel and ethinyl estradiol together with placebo manufactured in the same capsule for four consecutive cycles with a seven-day interval between them. The other 23 patients (group 2) took the same oral contraceptive together with estriol, which was put into the same capsule and used in the same way as among the group 1 patients. After four cycles, the nodules were surgically removed and sent for immunohistochemical analysis of Ki-67 and c-myc expression. RESULTS: The Ki-67 and c-myc analysis did not reveal any significant differences between the study groups. The values were 9.16 and 10.54 for group 1 and 10.86 and 17.03 for group 2, respectively. There was a tendency towards higher expression of antigens in group 2. CONCLUSION: Our results showed that there was no significant statistical difference in Ki-67 and c-myc expression between our study groups, but only a tendency towards higher expression among users of oral contraceptives containing estriol.
- ItemAcesso aberto (Open Access)Ensaio clínico randomizado com o uso de laser de CO2 fracionado e estrogênio vaginal no tratamento da síndrome genito urinária em mulheres pós menopausa(Universidade Federal de São Paulo (UNIFESP), 2020-08-27) Dutra, Paula Fernanda Santos Pallone [UNIFESP]; Speck, Neila Maria De Gois [UNIFESP]; Universidade Federal de São PauloIntroduction: Genitourinary syndrome (SGU) is a chronic and progressive disease common in postmenopausal women and defines a set of symptoms and signs associated with estrogen deficit in Organs genitourinary organs. It is estimated that SGU affects about 50% of post-menopausal women, negatively impacting quality of life. Among the most common symptoms we can mention vaginal dryness, pain on intercourse, vulvovaginal itching and urinary infections. Topical estrogen therapy is the treatment of choice and the most effective for SGU. However, some women have specific contraindications for hormonal therapy or, even, do not respond to the topical dose used for treatment. In this context, the evaluation of new alternative non- hormonal treatments will allow a peculiar group of women to have access to the treatment of symptoms resulting from vulvovaginal atrophy. Objectives: To compare the effectiveness of using fractional CO2 laser and vaginal topical estriol in genitourinary syndrome. Subjects and Methods: A randomized clinical trial was carried out, involving 25 postmenopausal women, selected, between February 2017 and February 2018. It included women, between 50 and 65 years old, with at least 1 year of amenorrhea and FSH above 40 IU / L, being followed up at the Ambulatory of Pathology of the Lower Genital Tract and Colposcopy - UNIFESP and that met the inclusion criteria of the work. The women were randomly randomized into two groups, with 13 women in the laser group and 12 women in the group that would use vaginal estrogen therapy. Subjective evaluation was performed through physical examination and colposcopy, analysis of the cell maturation index and sexual function before and after the treatments proposed for each group and histomorphometric analysis of the vaginal epithelium. Statistical analysis was performed using: Shapiro-Wilk to verify the assumption of Normality of the numerical information; t-Student for independent samples when comparing groups (estrogen, laser), according to numerical information with Normal distribution; Chi-square or Fisher's exact test when comparing groups (estrogen, laser), according to marital status and education; Mann- Whitney in the comparison of groups (estrogen, laser), according to age at the beginning of menopause and analysis of variance (ANOVA) with repeated measures in the comparison of epithelial thickness, Female Sexual Quotient (QSF), number of deep, intermediate and superficial (FROST) and maturation index between groups (estrogen, laser) and times (initial, final); in addition to multiple Bonferroni 12 comparisons when needed. In all conclusions obtained through inferential analyzes, an alpha significance level of 5% was used and statistical analyzes were performed using the statistical programs IBM-SPSS Statistics version 24 and R version 3.6.3. Results: The evaluation through physical examination showed an important improvement in trophic aspects in both groups. Regarding cell maturation, there was a tendency for the estrogen group to increase when compared to laser. Sexual function, assessed using the Female Sexual Quotient (QSF), showed a significant increase over time, both in the estrogen group (p <0.001) and in the laser group (p <0.001). In histological analysis, both fractional CO2 laser (p <0.001) and estrogen therapy (p = 0.001), showed a significant increase in the thickness of the vaginal epithelium at the end of treatment. Conclusion: CO2 fractional laser can be considered an effective method for the treatment of vulvovaginal atrophy similarity to standard estrogen treatment.